Sign in
Taking people in United StatesNo phase

Osilodrostat with steroid replacement in people with Cushing syndrome

Looks at how often adrenal insufficiency occurs with osilodrostat plus glucocorticoid replacement in Cushing syndrome.

Key facts

Who runs it
University of Michigan
Where
Ann Arbor, United StatesSee the site
Trial code
Registry title
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
Status
Recruiting
People taking part
12 people, planned
Started
19 Jul 2024
Expected to end
Jan 2028
Type of study
Observational
Treatments tested
  • Osilodrostat
Record updated
9 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with endogenous Cushing syndrome, meaning the body itself makes too much cortisol. They will get osilodrostat together with glucocorticoid replacement as part of their usual care.

Age
18 Years to 75 Years
Sex
All sexes can join.
Disease stage
Endogenous Cushing syndrome, either after surgery or in people who cannot have surgery.
Earlier treatment
People must be under consideration to receive osilodrostat as part of their clinical care. People who had other investigational (trial) drugs within 30 days or five half-lives, whichever is longer, cannot join.

Main reasons for not taking part

  • Treatment with other investigational drugs within 30 days or five half-lives, whichever is longer
  • Past allergic reaction to osilodrostat or similar medicines

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Endogenous Cushing syndrome, either following surgery or not candidates for surgery
  • Under consideration to receive osilodrostat as part of their clinical care
  • Able to provide informed consent

Who cannot take part

  • Treatment with other investigational drugs within 30 days or five half-lives (whichever is longer)
  • A history of hypersensitivity to osilodrostat or therapies of a similar chemical class

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Eyad AlsafadiTaking people

About the trial

What the trial wants to find out

The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach).

Read full original descriptionShow less

The investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.

The group in the trial

  • Observational cohort

    Participants with Cushing syndrome consented to participate in block-and-replace osilodrostat therapy.

    Treatment: Osilodrostat

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
Plain-language title
Osilodrostat with steroid replacement in people with Cushing syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06430528, who can take part
Record updated
9 September 2026